PULSED AF Post-Approval Study

Medtronic Cardiac Ablation Solutions

Status

Enrolling

Conditions

Atrial Fibrillation

Treatments

Device: PulseSelect™ PFA system

Study type

Observational

Funder types

Industry

Identifiers

NCT06578104

PULSED AF PAS

Details and patient eligibility

About

PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

Full description

PulseSelect is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months. Study visits will occur at 3, 6, 12, 24, and 36 months post-ablation, including required 24-hour Holter monitoring at 6, 12, 24, and 36 month visits. The PulseSelect™ PFA System used in this study is market approved and the ablation procedure will be performed according to hospital standard of care.

Enrollment

580 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

A diagnosis of recurrent symptomatic paroxysmal AF or persistent AF
Failure or intolerance of at least one Class I or III antiarrhythmic drug
Patient is ≥ 18 years of age
Planned pulmonary vein isolation procedure with the commercially available PulseSelect™ PFA System
Willing and able to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion criteria

Long-standing persistent AF (continuous AF sustained >12 months)
Prior left atrial ablation or left atrial surgical procedure
Patient with life expectancy < 36 months
Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
Current or anticipated participation in any other clinical trial of a drug, device, or biologic not approved by the global study manager